恩瑞格治疗铁质积聚效果怎么样呢？

(Deferasirox) is an oral iron chelator that was approved by the FDA in 2005 for the treatment of chronic iron overload caused by blood transfusions. The original research was by Novartis Pharmaceuticals. In January 2013, the FDA approved expanded indications to treat chronic iron overdose caused by Non-Transfusion Dependent Thalassemia Syndromes (NTDT), making Enrige the first drug to treat this indication. Today we will take a look at the effect of Enrige in treating iron accumulation?

According to a retrospective study in Italy, 42.7% of patients achieved a hematological response and reduced the need for blood transfusions after receiving chelation therapy with DFO or Deferasirox. There may be a dynamic, bidirectional regulatory mechanism between erythropoiesis and iron overload. On the one hand, ineffective erythropoiesis can lead to increased intestinal iron absorption through reduced hepcidin secretion by the liver. On the other hand, chelation treatment of iron overload can improve erythropoiesis, increase hemoglobin levels, and reduce clinical blood transfusions.

The results of a single-arm, multi-center, prospective clinical study involving 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of Enrig in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that Enrig can improve organ function in patients with iron overload. The results of the TELESTO study released at the ASH 2018 meeting also proved that Enrige continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.

In summary, iron overload increases the risk of infection, endocrine system damage, vital organ dysfunction, AML transformation in MDS patients, and shortens survival. Iron chelators are currently the mainstream treatment for iron removal. Among them, Enrige is easy to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment.

Enrig is more convenient and has higher patient compliance. EPIC is currently the largest prospective, open, single-group, global multi-center clinical study designed for patients with iron overload. A total of 341 MDS patients were enrolled, and it could reduce serum ferritin by an average of 372 μg/L in 3 months.

The above is the content of the treatment effect, I hope it can help you!